Tiffanie McDowell
Areas of Focus
Overview
Tiffanie McDowell is a partner in Crowell & Moring’s Orange County office, where she practices in the firm’s Antitrust and Competition and Health Care groups. Tiffanie has deep experience in pharmaceutical drug pricing and issues that impact access to pharmaceutical drugs.
Career & Education
- University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
- University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
- University of Missouri, B.S., cum laude, political science, 2006
- University of Missouri, B.A., cum laude, international studies, 2006
- University of Missouri, B.B.A., cum laude, international business, 2006
- California
Tiffanie's Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 7 min read | 11.02.26
Client Alert | 5 min read | 10.22.26
CMS Proposes Major Changes to MA, Part D, and PBM Requirements
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
Insights
Tripped at Customs: EU Seizures of Indian Generic Pharmaceutical Drugs in Transit
|08.19.15
Practitioner Treatise on International Business Vol. 2, Ralph Folsom ed.
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
|03.04.26
“Partnering to Maximize and Regularize Returns,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
|03.04.26
Industries
Tiffanie's Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 7 min read | 11.02.26
Client Alert | 5 min read | 10.22.26
CMS Proposes Major Changes to MA, Part D, and PBM Requirements
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations




